In adult patients with chronic liver disease, which vasoactive agent—vasopressin or terlipressin—is preferred as first‑line therapy for hepatorenal syndrome‑acute kidney injury or acute variceal hemorrhage, and what are the recommended dosing regimens?

Vasopressin vs Terlipressin in Chronic Liver Disease

Neither vasopressin nor terlipressin should be used for acute variceal hemorrhage—octreotide is the vasoactive drug of choice for this indication based on its superior safety profile. For hepatorenal syndrome-acute kidney injury (HRS-AKI), terlipressin is the preferred first-line vasoactive agent, while vasopressin is not recommended at all in cirrhosis due to unacceptable cardiovascular toxicity 1.

For Acute Variceal Hemorrhage

Vasopressin is no longer advised in patients with acute variceal hemorrhage because of a high risk of cardiovascular adverse events 1. The 2024 AGA guidelines explicitly state that octreotide is the vasoactive drug of choice for variceal bleeding management 1.

Why Not Terlipressin or Vasopressin for Variceal Bleeding?

• A 2021 meta-analysis of 21 RCTs showed that terlipressin or vasopressin compared with octreotide or somatostatin resulted in similar efficacy (mortality, hemostasis, rebleeding rates) but adverse events increased by 2.39-fold 1
• Specific adverse events that were considerably increased: abdominal pain, chest pain, diarrhea, and hyponatremia 1
• Another meta-analysis of 3,344 patients from 30 RCTs found terlipressin was less effective than octreotide for bleeding control within 24 hours and had higher complication rates than somatostatin 1

Terlipressin Contraindications (Critical for Variceal Bleeding Context)

Terlipressin is contraindicated in patients with 1, 2:

• Hypoxia or worsening respiratory symptoms (SpO2 <90%)
• Ongoing coronary, peripheral, or mesenteric ischemia
• Should be used with extreme caution in ACLF Grade 3

For Hepatorenal Syndrome-Acute Kidney Injury (HRS-AKI)

Terlipressin is the vasoactive drug of choice for HRS-AKI 1, 3. Vasopressin is not mentioned as a treatment option in current guidelines for HRS-AKI—it has been abandoned due to safety concerns.

Recommended Terlipressin Dosing for HRS-AKI

The FDA-approved regimen 2:

Days 1-3:

• 0.85 mg IV every 6 hours (slow bolus over 2 minutes)

Day 4 Assessment:

• If serum creatinine (SCr) decreased ≥30% from baseline: continue 0.85 mg every 6 hours
• If SCr decreased <30% from baseline: increase to 1.7 mg (2 vials) every 6 hours
• If SCr at or above baseline: discontinue terlipressin

Duration:

• Continue until 24 hours after two consecutive SCr ≤1.5 mg/dL values at least 2 hours apart
• Maximum 14 days of treatment

Continuous Infusion vs Bolus Dosing

Emerging evidence supports continuous infusion over bolus dosing 1:

• Single-center RCTs from India showed continuous infusion (4 mg/24h) vs bolus (2 mg every 4h) resulted in greater hepatic venous pressure gradient reduction and lower rebleeding rates 1
• Continuous infusion allows lower total doses with fewer adverse events 4, 5
• A 2026 meta-analysis showed continuous infusion reduced treatment failure, rebleeding, and total adverse events compared to bolus 4

Albumin Co-Administration

Concurrent IV albumin should be considered when accounting for patient's volume status 1, 3. The 2021 AASLD guidance states terlipressin should be given "in combination with albumin" 3.

Alternative Agents When Terlipressin Unavailable

If terlipressin is not available 3:

1. Norepinephrine (second-line)
2. Midodrine (5-15 mg PO every 8h) + octreotide (100-200 μg every 8h or 50 μg/h IV) - though efficacy is low

Important caveat: A 2020 RCT in ACLF patients showed terlipressin was superior to norepinephrine for HRS-AKI, with better day 4 and day 7 response rates (41.7% vs 20%), better HRS reversal (40% vs 16.7%), reduced need for renal replacement therapy (56.6% vs 80%), and improved 28-day survival (48.3% vs 20%) 6.

Critical Safety Monitoring

Before Initiating Terlipressin

• Assess baseline oxygen saturation (SpO2) 2
• Assess ACLF grade and volume status 2
• Do not initiate if SpO2 <90% 2

During Treatment

• Continuous pulse oximetry monitoring 2
• Discontinue if SpO2 drops below 90% 2
• Monitor for ischemic events (cardiac, peripheral, mesenteric) 2
• Actively manage volume overload—reduce/discontinue albumin and other fluids, use diuretics judiciously 2

High-Risk Populations

• Patients unlikely to benefit: SCr >5 mg/dL 2
• Use with extreme caution: ACLF Grade 3, MELD ≥35 if listed for transplant 1
• Respiratory failure risk: 14% in terlipressin group vs 5% placebo in pivotal trial 2

Common Pitfalls to Avoid

1. Do not use vasopressin in any cirrhosis indication—it has been abandoned due to cardiovascular toxicity
2. Do not use terlipressin for variceal bleeding as first-line—octreotide is safer and equally or more effective
3. Do not initiate terlipressin in hypoxic patients—this is a boxed warning and contraindication 2
4. Do not continue terlipressin if SCr remains at/above baseline on Day 4—this predicts non-response 3
5. Do not forget liver transplant evaluation—all HRS-AKI patients should be urgently evaluated for transplant as medical therapy alone has poor outcomes 3

Key Adverse Event Profile Comparison

Terlipressin (≥10%): Abdominal pain, nausea, respiratory failure, diarrhea, dyspnea 2

Terlipressin (<10% but serious): Myocardial ischemia, stroke, intestinal ischemia, fluid overload, pleural effusion 1

Vasopressin: Similar to terlipressin but with higher cardiovascular event rates—this is why it's no longer used 1